Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

Core Insights - Theriva Biologics has successfully engaged with the FDA, allowing the advancement into a proposed Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC) [1][4] Group 1: Clinical Trial Design and Feedback - The FDA has provided general agreement on Theriva's proposed design for the Phase 3 clinical trial, which is aligned with the successful VIRAGE Phase 2 trial that demonstrated improved overall survival (OS), progression-free survival (PFS), and Duration of Response (DoR) in patients receiving VCN-01 with standard-of-care chemotherapy [2] - The Phase 3 trial will include repeat dosing of VCN-01 and an adaptive design to optimize timelines and outcomes, based on the positive results from the Phase 2 trial [2][4] - The FDA has indicated that a potential biologics licensing application (BLA) for VCN-01 could be supported by the proposed Phase 3 trial, which will compare VCN-01 plus chemotherapy to chemotherapy plus placebo [3] Group 2: Company Strategy and Future Plans - The combined feedback from the FDA and EMA allows the company to finalize the protocol for the pivotal Phase 3 clinical trial and pursue strategic funding opportunities [1][4] - The CEO of Theriva Biologics expressed optimism that administering multiple macrocycles of VCN-01 alongside chemotherapy may further enhance patient outcomes [4] - The company aims to deliver a novel treatment option for patients with difficult-to-treat solid tumors, leveraging the insights gained from regulatory feedback [4] Group 3: Background on PDAC and VCN-01 - Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of pancreatic tumors and is often diagnosed at advanced stages, making treatment challenging [5] - VCN-01 is an oncolytic adenovirus designed to selectively replicate within tumor cells, degrade tumor stroma, and enhance the efficacy of co-administered chemotherapy [6][7] - The therapeutic approach of VCN-01 aims to improve access to chemotherapy and stimulate an immune response against the tumor [7]